TESARO (TSRO) Misses Q4 EPS Views; Announces 4.4M Share Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TESARO Announces Fourth-Quarter 2015 Operating Results
February 25, 2016 4:07 PM ESTU.S. commercial launch of VARUBI® (oral rolapitant) well underwayNiraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitorNew Drug Application (NDA) submission for niraparib planned for 2H 2016Investigational New Drug (IND) application for TSR-042 cleared by FDAIND submission for TSR-022 (anti-TIM-3 antibody) planned for Q2 2016Cash and cash equivalents totaled $230.1 million as of December 31, 2015Private placement financing will add an additional $155 million upon... More
TESARO Announces Definitive Agreement for $155 Million Private Placement
February 25, 2016 4:05 PM ESTWALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors to sell 4.4 million shares of its common stock at $35.19 per share in a private placement, resulting in proceeds of $155 million. The offering price per share of $35.19 is based upon the volume weighted average price of TESAROs common stock for the ten consecutive trading days ending February 22, 2016. Â
Existing investors affiliated with InterWest Partners, Kleiner Perkins Caufield and Byers and New Enterprise Associates,... More
